title: Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies.
abstract: Excess of bone remodeling is still the major pathogenic factor in involutional osteoporosis. This phenomenon is linked to an imbalance between neoformation (by osteoblasts) and resorption (by osteoclasts). Recently, research in drug development is focused on new and more "physiological" approach to balance bone remodeling. The efficacy of denosumab was proved in the prevention of vertebral and non-vertebral fractures and related to the ability of the drug to penetrate in cortical and trabecular bone. Recently, data from several clinical studies confirm that denosumab improves fracture outcomes, also at skeletal sites rich in cortical bone.
authors.affiliation: Department of Medical and Surgical Specialties and Dentistry, Second University of Naples, Naples, Italy, giovanni.iolascon@gmail.com.
authors.forename: G
authors.initials: G
authors.lastname: Iolascon
authors.forename: G
authors.initials: G
authors.lastname: Resmini
authors.forename: U
authors.initials: U
authors.lastname: Tarantino
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects*; D000069448:Denosumab; D005260:Female; D017102:Fracture Healing; D006801:Humans; D010006:Osteoblasts / Q000187:drug effects; D010010:Osteoclasts / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy; D015663:Osteoporosis, Postmenopausal; D058866:Osteoporotic Fractures / Q000453:epidemiology / Q000517:prevention & control*; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069448:Denosumab